DIRECT - Innovative Medicines Initiative:
DIabetes REsearCh on patient straTification

Work Package 4 (WP4):
Genetic and genomic analyses supporting biomarker identification and characterisation

Studies of WP4 will provide genomic and genetic analyses in phenotypically well-characterised samples available to the DIRECT Consortium to identify sets of biomarkers of potential clinical value with respect to disease progression and treatment response. This will be done by generating and analysing high-quality, large-scale genetic and genomic data from the biological samples collected from patients in the studies described in both WP2 and WP3 and by functional genomics studies designed to provide mechanistic insights into key processes associated with disease progression and treatment response.

WP4 will be to provide genetic and genomic data in genetic discovery, transcriptional and functional genomics, proteomics, metabolomics and metagenomics. Therefore, WP4 will cooperate closely with WP2 and WP3 to define the most efficient set of genetic and genomic analyses within the key study cohorts, and with WP5 to incorporate the data generated into the DIRECT database and make them available for multi-omic analysis in WP5.

The best biomarkers will be selected for the assay development and validation in the WP6.

  • Sanofi-Aventis Deutschland GmbH
  • University of Dundee
  • Technical University of Denmark
  • Helmholtz Zentrum München – Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH
  • Consorci Institut D´Investigacions Biomediques August Pi i Sunyer
  • Imperial College London
  • Kungliga Tekniska Högskolan
  • University of Lille - CNRS
  • Leiden University Medical Center
  • University of Copenhagen
  • Lunds Universitet
  • Université de Genève
  • The Chancellor, Masters and Scholars of the University of Oxford
  • Eli Lilly and Company Ltd.